182 related articles for article (PubMed ID: 38335394)
41. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
43. Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.
Labrosse J; Abdennebi I; Thibault L; Laas E; Merckelbagh H; Morel C; Lam T; Lae M; Reyal F; Hamy AS
Breast; 2018 Dec; 42():61-67. PubMed ID: 30179779
[TBL] [Abstract][Full Text] [Related]
44. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
[TBL] [Abstract][Full Text] [Related]
45. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
[TBL] [Abstract][Full Text] [Related]
46. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer:A multicenter study.
Li B; Li F; Liu Z; Xu F; Ye G; Li W; Zhang Y; Zhu T; Shao L; Chen C; Sun C; Qiu B; Bu H; Wang K; Tian J
Breast; 2022 Dec; 66():183-190. PubMed ID: 36308926
[TBL] [Abstract][Full Text] [Related]
47. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
[TBL] [Abstract][Full Text] [Related]
48. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
49. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.
Hong J; Rui W; Fei X; Chen X; Shen K
Cancer Med; 2021 Nov; 10(22):7921-7933. PubMed ID: 34562054
[TBL] [Abstract][Full Text] [Related]
50. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
Wang K; Xu J; Zhang T; Xue D
Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588
[TBL] [Abstract][Full Text] [Related]
51. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
52. Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.
Russo L; Maltese A; Betancourt L; Romero G; Cialoni D; De la Fuente L; Gutierrez M; Ruiz A; Agüero E; Hernández S
Eur J Surg Oncol; 2019 Jun; 45(6):963-968. PubMed ID: 30745134
[TBL] [Abstract][Full Text] [Related]
53. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
[TBL] [Abstract][Full Text] [Related]
54. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
56. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
[TBL] [Abstract][Full Text] [Related]
57. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer.
Zhang G; Xie W; Liu Z; Lin C; Piao Y; Xu L; Guo F; Xie X
Tumori; 2014; 100(2):136-42. PubMed ID: 24852856
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.
Khoury T; Nagrale V; Opyrchal M; Peng X; Wang D; Yao S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):523-532. PubMed ID: 28187033
[TBL] [Abstract][Full Text] [Related]
59. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
60. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]